openPR Logo
Press release

Hypertrophic Scars Therapeutics Analysis by Key Players - RXi Pharmaceuticals Corporation, Sirnaomics, ScarX Therapeutics, Scarless Laboratories

11-14-2018 07:57 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: P&S Intelligence

Hypertrophic Scars Therapeutics Analysis by Key Players - RXi

According to P&S Intelligence, Hypertrophic scars currently exhibits a growing pipeline with nine drug candidates.

Body cells known as myofibroblasts produce excessive collagen during healing process which can be deposited as a bump and later changes to a hypertrophic scar. The study analyzed that the hypertrophic scars therapeutics pipeline comprises approximately nine drug candidates in different stages of development.

Browse report sample at: https://www.psmarketresearch.com/market-analysis/hypertrophic-scars-therapeutics-pipeline-analysis/report-sample

The drug development process involves specific targets such as connective tissue growth factor inhibition which is the probable mechanism of action for the treatment of hypertrophic scars. Thus, this specific targeted therapy provides opportunities to the companies for better and targeted drug development.

Technological advancements have been strengthening the development of pipeline drugs for the treatment of hypertrophic scars. For instance, The RNA interference (RNAi) technology, was used in the development of OLX101 by OliX Pharmaceuticals, Inc.

Browse report at: https://www.psmarketresearch.com/market-analysis/hypertrophic-scars-therapeutics-pipeline-analysis

Some of the players developing drugs for the treatment of hypertrophic scars include RXi Pharmaceuticals Corporation, Sirnaomics, Inc., ScarX Therapeutics, Inc., and Scarless Laboratories, Inc.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
347 5th Ave. #1402- 210
New York City, NY 10016 United States
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hypertrophic Scars Therapeutics Analysis by Key Players - RXi Pharmaceuticals Corporation, Sirnaomics, ScarX Therapeutics, Scarless Laboratories here

News-ID: 1371002 • Views:

More Releases from P&S Intelligence

U.S. ESG Investments Market Set to Skyrocket: $16 Trillion by 2032
U.S. ESG Investments Market Set to Skyrocket: $16 Trillion by 2032
According to the latest market research study published by P&S Intelligence, the U.S. Environmental, Social, and Governance (ESG) investments market is experiencing a significant surge, with projections indicating an increase from $6.5 trillion in 2024 to an estimated $16.0 trillion by 2032. This represents a robust compound annual growth rate (CAGR) of 12.1% over the forecast period. According to a comprehensive analysis by P&S Intelligence, the market's expansion is driven
Facility Management in the U.K. Booms with 14.1% CAGR as Demand Soars Across Sectors
Facility Management in the U.K. Booms with 14.1% CAGR as Demand Soars Across Sec …
According to the latest market research study published by P&S Intelligence, the U.K. facility management market is poised for significant growth, with projected revenues reaching USD 2,743.3 million in 2024 and expected to soar to USD 6,038.4 million by 2030, reflecting a robust CAGR of 14.1% during the forecast period. This expansion is fueled by a surge in demand across both public and private sectors. According to the RICS U.K.
Point-of-Sale Software Market in the U.S. Set to Grow by 9.7% CAGR, Boosted by Omnichannel Integration
Point-of-Sale Software Market in the U.S. Set to Grow by 9.7% CAGR, Boosted by O …
According to the latest market research study published by P&S Intelligence, the U.S. point-of-sale (POS) software market, valued at USD 4.7 billion in 2024, is poised for significant growth over the coming years, with projections estimating it will reach USD 9.8 billion by 2032, expanding at a compound annual growth rate (CAGR) of 9.7%. This growth is attributed to rapid technological advancements, a surge in mobile and cloud-based POS systems,
Competitive Landscape of the Industrial Starches Market: Key Players, Trends, and Growth Opportunities
Competitive Landscape of the Industrial Starches Market: Key Players, Trends, an …
According to the latest market research study published by P&S Intelligence, the global industrial starches market is poised for significant growth, with a projected increase from USD 110.3 billion in 2024 to USD 169.9 billion by 2030, at a robust compound annual growth rate (CAGR) of 7.5%. Industrial starches play a crucial role in diverse sectors, including food, pharmaceuticals, and paper, driven by their unique properties such as stabilizing, thickening,

All 4 Releases


More Releases for Hypertrophic

Rising Obesity Rates Fuel Growth In Hypertrophic Cardiomyopathy Treatment Market …
The Hypertrophic Cardiomyopathy Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Hypertrophic Cardiomyopathy Treatment Market Size and Projected Growth Rate? The market size of treatment for hypertrophic cardiomyopathy has seen consistent growth in recent times. The size is projected to increase from
Evolving Market Trends In The Hypertrophic Cardiomyopathy (HCM) Therapeutics Ind …
The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Current Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size and Its Estimated Growth Rate? In the past few years, the hypertrophic cardiomyopathy (HCM) therapeutics market has seen a minor increase in its
Evolving Market Trends In The Hypertrophic Cardiomyopathy (HCM) Therapeutics Ind …
The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Current Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Size and Its Estimated Growth Rate? In the past few years, the hypertrophic cardiomyopathy (HCM) therapeutics market has seen a minor increase in its
Key Hypertrophic Cardiomyopathy Treatment Market Trend for 2025-2034: Innovative …
What Is the Future Outlook for the Hypertrophic Cardiomyopathy Treatment Market's Size and Growth Rate? The hypertrophic cardiomyopathy treatment market will grow from $1.37 billion in 2024 to $1.42 billion in 2025, at a CAGR of 4.2%. This growth is supported by advances in diagnostic technologies, drug therapies, surgical interventions, and clinical guidelines. The Hypertrophic Cardiomyopathy Treatment market will grow to $1.72 billion by 2029 at a CAGR of 4.9%. Growth is
Key Hypertrophic Cardiomyopathy Treatment Market Trend for 2025-2034: Innovative …
What Is the Future Outlook for the Hypertrophic Cardiomyopathy Treatment Market's Size and Growth Rate? The hypertrophic cardiomyopathy treatment market will grow from $1.37 billion in 2024 to $1.42 billion in 2025, at a CAGR of 4.2%. This growth is supported by advances in diagnostic technologies, drug therapies, surgical interventions, and clinical guidelines. The Hypertrophic Cardiomyopathy Treatment market will grow to $1.72 billion by 2029 at a CAGR of 4.9%. Growth is
Hypertrophic Cardiomyopathy Market - Empowering Lives, Elevating Heart Health: H …
Newark, New Castle, USA: The "Hypertrophic Cardiomyopathy Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Hypertrophic Cardiomyopathy Market: https://www.growthplusreports.com/report/hypertrophic-cardiomyopathy-market/8833 This latest report researches the industry structure, sales, revenue,